

<b>Track B – Clinical science</b>	
<b>Course of HIV disease</b>	
B1	Acute and early infection
B2	Morbidity, mortality and life expectancy
B3	Determinants of HIV progression and disease control
<b>Diagnostic and monitoring tools</b>	
B4	HIV testing and retesting
B5	Genotyping and viral tropism testing (viral and proviral)
B6	Viral load and CD4 measurement
B7	ART adherence measurement
B8	Drug resistance testing
B9	Diagnosis of co-infections and co-morbidities
<b>Co-infections (including opportunistic infections)</b>	
B10	Opportunistic infections (excluding tuberculosis)
B11	Tuberculosis and other mycobacteria
B12	Viral hepatitis A, B, D and E
B13	Viral hepatitis C
B14	Human papillomavirus
B15	Syphilis and other sexually transmitted infections
B16	SARS-CoV-2
B17	Other bacterial, viral and parasitic infections
<b>Co-morbidities and complications (including those related to ART)</b>	
B18	Neurologic disorders
B19	Depression and other psychiatric manifestations
B20	Malignancies (AIDS and non-AIDS related)
B21	Cardiovascular disease
B22	Bone disease
B23	Renal disease
B24	Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy)
B25	Hepatic complications (including NASH)
B26	Ageing with HIV (including polypharmacy and frailty)
B27	Immune reconstitution disorders and immune reconstitution inflammatory syndrome
B28	Other non-communicable diseases
B29	Other ART complications and adverse reactions
B30	Substance abuse (including opioid use disorder)
<b>Antiretroviral therapies in adults</b>	
B31	ART in acute infection
B32	ART in first- and second-line therapies
B33	ART in highly treatment-experienced people

B34	Management of late presenters
B35	Regimen simplification and switch studies
B36	Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring
B37	Drug interactions
B38	Antiretroviral drug resistance
B39	Long-acting agents and other drug delivery systems
B40	Adherence measurement
B41	Adherence promotion
B42	Ethical issues in clinical trials and treatment strategies
B43	New strategies (2DR, rapid start)
<b>Other strategies and therapies (including non-ART and cure)</b>	
B44	Therapeutic vaccine trials
B45	Immune-based therapy trials
B46	Cure interventions
B47	Novel therapeutic approaches (including gene therapy)
B48	Pain and palliative medicine
B49	Nutrition
B50	Complementary and traditional medicines
B51	Cure strategies in paediatric and adolescent populations
<b>Clinical issues specific to women</b>	
B52	Sex-specific issues of ART efficacy, adverse reactions and complications
B53	Pregnancy (clinical management issues and pharmacokinetics)
B54	Safe conception for serodiscordant couples
B55	Contraception
B56	Menopause
B57	Other sex- or gender-specific issues
<b>Clinical issues specific to paediatric and adolescent HIV</b>	
B58	Diagnosis of HIV disease in paediatric and adolescent populations
B59	Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations
B60	Drug formulations for infants and children
B61	Clinical trials in paediatric and adolescent populations
B62	ARV management strategies in paediatric and adolescent populations
B63	Adherence in paediatric and adolescent populations
B64	HIV complications and co-morbidities in paediatric and adolescent populations
B65	HIV-associated co-infections and malignancies in paediatric and adolescent populations
B66	Behavioural health outcomes in paediatric and adolescent populations
B67	Mental health and neurocognition in paediatric and adolescent populations
B68	HIV-exposed uninfected children

B69	Transition of adolescents into adult care
<b>Clinical issues specific to key populations</b>	
B70	Clinical issues in men who have sex with men
B71	Clinical issues in people who use drugs
B72	Clinical issues in sex workers
B73	Clinical issues in transgender and non-binary populations
B74	Clinical issues in indigenous populations
B75	Clinical issues in migrant populations
B76	Clinical issues in other vulnerable populations
<b>COVID-19 and HIV</b>	
B77	COVID-16 disease manifestations in PLWH
B78	COVID-19 morbidity and mortality in PLWH
B79	COVID-19 treatment in PLWHIV
B80	Immune responses against SARS-CoV2 in PLWHIV